Amplify ETFs announced on Tuesday (July 23) that it has launched the Amplify Seymour Cannabis ETF (ARCA:CNBSon the NYSE Arca.

The actively managed cannabis-focused exchange-traded fund (ETF) aims to expose investors to the “fast-developing global cannabis industry,” according to a press release.


Tim Seymour, CIO of Seymour Asset Management and CNBC’s Fast Money co-host, will be the ETF’s portfolio manager and will base decisions on factors including: public regulatory findings, third party research and his own evaluations of company financials.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

“The global legal cannabis industry is still very much in its infancy and presents an attractive growth opportunity for investors looking to capitalize on this emerging frontier,” said Seymour.

The Amplify Seymour Cannabis ETF currently has 25 holdings, all of which are federally legal in the countries in which they operate and fall within three categories: cannabis and hemp cultivation, agricultural technology and ancillary companies in the cannabis industry.

Eighty percent of the companies on the new ETF make 50 percent or more of their revenue from the cannabis and hemp markets.

Christian Magoon, CEO and founder of Amplify ETFs, said that the cannabis industry is experiencing “a new wave of potential use cases across multiple industries, and investors are eager to gain access to this emerging sector.”

In an interview with CNN, Seymour commented, “An active approach is the only way to invest in a sector like this that’s changing by the day. If you are investing in cannabis a year ago, your focus would be on different companies than now.”

Similar to other ETFs in the cannabis space, the Amplify Seymour Cannabis ETF has zeroed in on some of the industry’s largest names. Here’s a list of the top five holdings by weightage:

  • Aurora Cannabis (NYSE:ACB,TSX:ACB) — 8.36 percent
  • GW Pharmaceuticals (NASDAQ:GWPH) — 7.77 percent
  • Canopy Growth (NYSE:CGC,TSX:WEED) — 7.75 percent
  • OrganiGram Holdings (TSXV:OGI,OTCQX:OGRMF) — 7.12 percent
  • HEXO (TSX:HEXO,NYSE:HEXO) — 5.92 percent
 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

Other cannabis heavyweights like Tilray (NASDAQ:TLRY) and Emerald Health Therapeutics (TSXV:EMH,OTCQX:EMHTF) are also included.

This announcement comes after the launch of another cannabis-focused ETF, Innovation Shares’ Cannabis ETF (ARCA:THCX), earlier this month, furthering the trend of cannabis-focused ETFs in the US.

Other additions to the space include the Evolve US Marijuana ETF (NEO:USMJ) from Evolve Funds Group and the Horizons US Marijuana Index ETF (NEO:HMUS) from Horizons ETFs Management, both of which launched on the NEO Exchange earlier this year.

Net assets for the Amplify Seymour Cannabis ETF currently sit at US$2.47 million, which is smaller than its counterparts. The Evolve US Marijuana ETF has US$3.95 million in assets under management and the Horizons US Marijuana Index ETF has US$15.85 million in assets.

Other US-based cannabis ETFs include the US$58.12 million AdvisorShares Pure Cannabis ETF (ARCA:YOLO) as well as the largest of the bunch at US$1.15 billion in assets, the ETFMG Alternative Harvest ETF (ARCA:MJ).

On Tuesday, Amplify Seymour Cannabis opened at US$24.65.

Don’t forget to follow us @INN_Cannabis for real-time updates!

Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

Appointment of Dr. Kelmendi, Assistant Professor of Psychiatry at Yale University and co-founder of the Yale Psychedelic Science Group, brings another experienced medical professional to Lobe’s advisory team.

 Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the appointment of Benjamin Kelmendi, MD, Assistant Professor of Psychiatry at Yale University School of Medicine, to its Scientific Advisory Board.

Keep reading... Show less

Ayurcann Holdings Corp. ( CSE: AYUR ) (the “ Company ” or ” Ayurcann “), a Canadian extraction company specializing in the processing of cannabis and hemp for the production of oils and various derivative products, is pleased to unveil further details of its Phase 2 expansion plans.

Ayurcann has commenced trading on the Canadian Securities Exchange (” CSE “) on April 8, 2021 and subsequently announced a private placement of up to $500,000 (” Financing “), as per the Company’s press release dated April 12, 2021. The proceeds of the Financing are intended to be used to further pursue Phase 2 of the expansion of the production capacity of the Company’s Pickering facility.

Keep reading... Show less

New findings suggest the COVID-19 pandemic, combined with expanded state legalization, has attracted new consumers to the category and accelerated cannabis acceptance and adoption.

  • YouGov study indicates the number of current cannabis consumers has increased 56% within just two years compared to the 16% of Americans who reported current consumption in 2018.
  • 23% of current consumers say they tried cannabis for the first time within the past year.
  • More than half of cannabis consumers say they will purchase or try a new product or format this 420, indicating that the holiday is becoming increasingly focused on exploration and trial.

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or the “Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, released the results of a survey today showing one in four Americans currently consume cannabis, reporting they’ve tried some form of cannabis within the past twelve months. That’s a significant increase since 2018* when just 16% of U.S. adults reported current consumption, representing a 56% increase in just two years. What’s more, 23% of current cannabis consumers say they tried cannabis for the first time over the past year, suggesting the COVID-19 pandemic, combined with expanded state legalization, has rapidly accelerated cannabis acceptance and adoption in America.

Keep reading... Show less

Acquires Three Operating Dispensaries in Northeast Pennsylvania

Purchase price represents a mid-single digit multiple of KCR’s expected 2021 EBITDA

Keep reading... Show less